$438 Million is the total value of Tamarack Advisers, LP's 29 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 45.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDT | Sell | MEDTRONIC PLCequity | $43,844,000 | +0.9% | 385,000 | -3.8% | 10.02% | -11.5% |
| BIO | Sell | BIO-RAD LABORATORIES-Aequity | $36,670,000 | -4.2% | 100,000 | -13.0% | 8.38% | -16.0% |
| MDRX | Sell | ALLSCRIPTS HEALTHCARE SOLUTIequity | $35,150,000 | -24.2% | 3,650,000 | -13.6% | 8.03% | -33.6% |
| ATRC | Buy | ATRICURE INCequity | $27,916,000 | +31.7% | 860,000 | +1.2% | 6.38% | +15.5% |
| PCRX | Sell | PACIRA BIOSCIENCES INCequity | $27,813,000 | -5.7% | 622,500 | -19.7% | 6.36% | -17.3% |
| DGX | Buy | QUEST DIAGNOSTICS INCequity | $25,745,000 | +37.5% | 245,000 | +40.0% | 5.88% | +20.5% |
| HOLX | Buy | HOLOGIC INCequity | $24,648,000 | +74.4% | 475,000 | +69.6% | 5.63% | +52.9% |
| ISEE | Sell | IVERIC BIO INCequity | $21,571,000 | +542.0% | 2,650,000 | -11.7% | 4.93% | +463.3% |
| SRCL | Sell | STERICYCLE INCequity | $18,591,000 | +4.3% | 300,000 | -14.3% | 4.25% | -8.5% |
| ZBH | Sell | ZIMMER BIOMET HOLDINGS INCequity | $18,594,000 | -15.3% | 125,000 | -21.9% | 4.25% | -25.8% |
| JNJ | New | JOHNSON & JOHNSONequity | $18,035,000 | – | 125,000 | +100.0% | 4.12% | – |
| PHR | Buy | PHREESIA INCequity | $17,549,000 | +262.0% | 660,000 | +230.0% | 4.01% | +217.5% |
| PTLA | Sell | PORTOLA PHARMACEUTICALS INCequity | $14,268,000 | -46.8% | 595,000 | -40.5% | 3.26% | -53.3% |
| ITGR | Buy | INTEGER HOLDINGS CORPequity | $13,367,000 | +53.8% | 165,000 | +43.5% | 3.05% | +34.9% |
| UTHR | Buy | UNITED THERAPEUTICS CORPequity | $13,090,000 | +118.9% | 151,400 | +101.9% | 2.99% | +92.0% |
| ICUI | Buy | ICU MEDICAL INCequity | $12,985,000 | +132.5% | 70,000 | +100.0% | 2.97% | +103.8% |
| LNTH | Sell | LANTHEUS HOLDINGS INCequity | $12,474,000 | -33.6% | 650,000 | -13.3% | 2.85% | -41.8% |
| RIGL | Buy | RIGEL PHARMACEUTICALS INCequity | $11,788,000 | +15.1% | 5,750,000 | +5.0% | 2.69% | +0.9% |
| MYL | New | MYLAN NVequity | $9,090,000 | – | 450,000 | +100.0% | 2.08% | – |
| OPTN | Buy | OPTINOSE INCequity | $8,568,000 | +81.3% | 1,050,000 | +55.6% | 1.96% | +59.1% |
| RDNT | Buy | RADNET INCequity | $8,268,000 | +77.2% | 400,000 | +23.1% | 1.89% | +55.3% |
| STRM | Buy | STREAMLINE HEALTH SOLUTIONSequity | $5,985,000 | +162.7% | 4,305,882 | +105.0% | 1.37% | +130.1% |
| INGN | New | INOGEN INCequity | $4,976,000 | – | 75,000 | +100.0% | 1.14% | – |
| NVRO | Sell | NEVRO CORPequity | $4,720,000 | +3.9% | 40,000 | -24.3% | 1.08% | -9.0% |
| CORV | Sell | CORREVIO PHARMA CORPequity | $1,019,000 | -88.7% | 2,500,000 | -44.4% | 0.23% | -90.1% |
| Buy | SPY US 01/17/20 P310put | $512,000 | -39.8% | 8,000 | +60.0% | 0.12% | -47.1% | |
| New | CRL US 01/17/20 C140call | $279,000 | – | 218 | +100.0% | 0.06% | – | |
| New | JNJ US 01/17/20 C140call | $125,000 | – | 250 | +100.0% | 0.03% | – | |
| New | HAE US 01/17/20 C125call | $24,000 | – | 500 | +100.0% | 0.01% | – | |
| Exit | IWM US 10/18/19 C160call | $0 | – | -10,000 | -100.0% | -0.03% | – | |
| Exit | MEDP US 12/20/19 P75put | $0 | – | -350 | -100.0% | -0.03% | – | |
| Exit | MDRX US 10/18/19 C10call | $0 | – | -2,000 | -100.0% | -0.05% | – | |
| Exit | ABT US 10/18/19 P85put | $0 | – | -900 | -100.0% | -0.06% | – | |
| Exit | XLV US 10/18/19 P90put | $0 | – | -5,000 | -100.0% | -0.14% | – | |
| GWPH | Exit | GW PHARMACEUTICALS -ADRdepository receipt | $0 | – | -25,000 | -100.0% | -0.75% | – |
| HMSY | Exit | HMS HOLDINGS CORPequity | $0 | – | -225,000 | -100.0% | -2.02% | – |
| CMD | Exit | CANTEL MEDICAL CORPequity | $0 | – | -135,000 | -100.0% | -2.63% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERADIGM ORD | 32 | Q3 2023 | 13.9% |
| STREAMLINE HEALTH SOLUTIONS ORD | 30 | Q3 2023 | 4.0% |
| ATRICURE ORD | 29 | Q3 2023 | 7.6% |
| PACIRA PHARMACEUTICALS INC | 27 | Q1 2023 | 12.1% |
| LANTHEUS HOLDINGS ORD | 25 | Q4 2022 | 9.6% |
| MEDTRONIC PLC | 21 | Q1 2022 | 12.7% |
| RIGEL PHARMACEUTICALS ORD | 21 | Q2 2023 | 8.0% |
| BIO RAD LABORATORIES CL A ORD | 19 | Q2 2023 | 10.0% |
| HOLOGIC INC | 17 | Q1 2022 | 6.5% |
| SPY US 10/21/16 P210 | 17 | Q3 2023 | 41.5% |
View Tamarack Advisers, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTIONS INC. | June 22, 2023 | 5,514,515 | 9.4% |
| IVERIC bio, Inc. | February 16, 2021 | 850,000 | 0.1% |
| Correvio Pharma Corp. | February 14, 2020 | 2,500,000 | 4.9% |
| OBALON THERAPEUTICS INC | February 14, 2020 | ? | ? |
| Correvio Pharma Corp. | February 15, 2019 | ? | ? |
| Corium International, Inc. | February 15, 2017 | 737,242 | 3.3% |
| ENDOLOGIX INC /DE/Sold out | February 15, 2017 | 0 | 0.0% |
| Imprivata IncSold out | February 15, 2017 | 0 | 0.0% |
View Tamarack Advisers, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-16 |
| 13F-HR | 2023-08-10 |
| SC 13D/A | 2023-06-22 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-01 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-11 |
View Tamarack Advisers, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.